Titlebook: Clinical Pharmacology in Psychiatry; From Molecular Studi Svein G. Dahl (Professor of Pharmacology),Lars F. Conference proceedings 1989 Sp

maverick

Targets for Neurotransmitter Receptor Research Using PET Scan: The Neuroleptic Binding Sitevestigate in vivo in humans a variety of brain neuroreceptors (Baron 1987). With this method one obtains a series of transaxial tomographic brain images that quantitatively represent the specifically bound radioligand an (“in vivo receptor autoradiography”). Various approaches and models have been a

徹底明白

outrage

Herbivorous

E-10-Hydroxynortriptyline: Effects and Disposition of a Potential Novel Antidepressant When similar doses of nortriptyline are given, the plasma levels vary extensively among individual patients (Sj?qvist, this volume). This is due to the great variation in the liver cytochrome P-450 enzyme, which hydroxylates nortriptyline. In several studies both in vivo and in vitro, we have shown

FIR

Negative Symptoms in Schizophrenia: A Target for New Drug Developmentschizophrenia. It is unclear whether other kinds of thought disorder, e. g., looseness of associations, are also positive symptoms. The most important clinical effect of the current major classes of antipsychotic drugs, e. g., phenothiazines, butyrophenones, and thioxanthenes, is their ability to el

商品

Carbon-Monoxide

Effects of Serotonergic Agonists on Neuroendocrine Responses of Rhesus Monkeys and Patients with Depany years. Recent progress in biochemical neuropharmacology has resulted in the delineation of a variety of serotonin receptor subtypes. More specific agonists and antagonists for the serotonin receptor subtypes are available, and a few are available for clinical use. One research strategy has been